Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
How to watch 2026 Golden Globe winners like 'One Battle After Another,' 'Adolescence' and 'The Pitt' - 2Police break up illegal chicken slaughter in Germany
- 3Violence 'never part' of break-in plan, court told
- 4Home Plan Tips for Seniors
- 5Triple polar vortex to plunge central and eastern U.S. into Arctic cold through mid-December
- I asked ChatGPT who would win a Golden Globes. Here's what it got right — and totally wrong.
- Gym tied to outbreak of obscure disease that spreads through mist
- Scientists find new clues to why female fertility declines with age
- Israeli archaeologists launch project to trace origins of ancient pottery
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Far reaching Guide
- Journey through Pages: A Survey of \Plunging into Scholarly Universes\
- A throat bone settles it - Nanotyrannus was not a juvenile T. rex
- 10 Asian Countries Perfect for Solo Female Travelers
- Kaiser Permanente affiliates to pay $556 million to resolve US claims alleging Medicare fraud
